Abstract: The present invention is directed to a monoclonal antibody or an antigen-binding portion thereof having specific binding affinity to RING finger protein 4 (RNF4). The invention is further directed to use of the antibody or an antigen-binding portion thereof in detecting a RNF4-associated disease in a subject, such as cancer.

Abstract: The present invention relates to compositions comprising erenumab and one or more erenumab variants, including isomerization variants, deamidation variants, acidic variants, and HMW species. Pharmaceutical formulations comprising the erenumab compositions and methods of using and characterizing the compositions are also described.

Abstract: The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to the epidermal growth factor receptor (EGFR) as a clinical target for treatment of neurological disorders, preferably in conjunction with neuropathic pain. The invention relates in more detail to compositions comprising inhibitors of EGFR.

Abstract: The present disclosure relates to methods of treating social dysfunction neurological disorders in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity, and to a method of treating seizures in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity. In some embodiments, the compound is IFN-?.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: Methods and pharmaceutical compositions for treatment of amyloid deposition diseases using chimeric (e.g., mouse-human) antibody are disclosed, including a method for treating amyloid deposition diseases with cardiac involvement by administering pharmaceutical compositions comprising a chimeric anti-amyloid fibril antibody. The methods herein can improve myocardial function in patients diagnosed with light chain amyloid light chain amyloidosis (ALA) having a cardiac involvement in as little as three weeks after treatment.

Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.

Abstract: Provided are epithelial cell spheroids including spheroids that have apical membranes and cilia that face towards the interior core of the spheroid and spheroids that have apical membranes and cilia that face away from the interior core of the spheroid. Also provided methods of making and using such spheroids.

Abstract: The present invention relates to a method for the early diagnosis and prognosis of an inflammatory state of the brain, caused by neurological, neurodegenerative, and/or aging diseases. Said method is based on the qualitative- quantitative evaluation of microglia microvesicles in a subject's plasma.

Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.

Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed. Specifically, methods for inhibiting, treating, and/or preventing inflammatory disease in patients in need thereof are provided. The methods comprise the administration of at least one antibody or antibody fragment immunologically specific for bridging integrator I (Bin 1), particularly the Myc binding domain.

Abstract: This invention relates to compounds (e.g., those delineated herein), pharmaceutically acceptable salts, prodrugs, solveates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering modulating compounds or compositions that modulate A?, PAMPS and DAMPS.

Abstract: The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention relates to a screening assay to produce compounds stabilizing the gamma-secretase enzyme substrate complex, thereby increasing gamma-secretase processivity while attenuating the release of longer A? peptides. More specifically, gamma-secretase stabilizing compounds increase thermostability of the enzyme/substrate complexes acting in the sequential ?-secretase processing of APP, to result in reduced amyloidogenic A? production, thereby preventing Alzheimer disease.

Abstract: The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.

Abstract: The present invention is directed to a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv binds to a tumor antigen, (ii) a transmembrane domain, (iii) a co-stimulatory domain of GITR intracellular domain, and (iv) an activating domain. In one embodiment, the tumor antigen is human epidermal growth factor receptor (EGFR), human mesothelin, or human CD19. CARs having GITR intracellular domain as a co-stimulatory domain have certain advantages over other traditional CAR co-stimulatory domains.

Abstract: The present invention provides an anti-APOA4 monoclonal antibody or an antibody fragment thereof capable of accurately measuring apolipoprotein A-IV (APOA4) in a specimen, a measurement method for immunologically measuring APOA4 using the antibody or the antibody fragment thereof, and a kit for measuring APOA4 containing the antibody or the antibody fragment thereof.

Abstract: A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain. An agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain is suitable for use in preventing, alleviating or treating traumatic brain injury. A method for predication of the risk of an individual for complications after a traumatic brain injury comprises detecting one or more aggregated forms of one or more peptides prone to aggregate as a result of a traumatic brain injury event, in the brain of the individual, wherein an increased level of such aggregates in the brain indicates an increased risk for complications.

Abstract: The invention provides compositions and methods for the preparation, manufacture and therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral genomes encoding one or more antibodies or antibody fragments or antibody like polypeptides, for the prevention and/or treatment of diseases and/or disorders.

Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.